← All CTA Flashcard Decks

CTA Biostatistics & Study Design Flashcards

6 cards from real CTA practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 6 CTA Biostatistics & Study Design flashcards as text
  1. Which type of clinical trial design randomly assigns participants to treatment or control groups to minimize bias?

    Answer: Randomized controlled trial (RCT)

    A randomized controlled trial (RCT) uses random assignment to treatment or control groups, which is the gold standard for minimizing selection bias in clinical research.

  2. In a double-blind clinical trial, who is unaware of the treatment assignment?

    Answer: Both the participant and the investigator

    In a double-blind study, both the participant and the investigator are unaware of treatment assignments to prevent performance and detection bias.

  3. What is a Phase I clinical trial primarily designed to evaluate?

    Answer: Safety and dosing in a small group of healthy volunteers

    Phase I trials are the first human studies focused on assessing safety, tolerability, and pharmacokinetics in a small group, typically healthy volunteers.

  4. What does the term 'placebo-controlled' mean in a clinical trial?

    Answer: A control group receives an inactive substance identical in appearance to the treatment

    In a placebo-controlled trial, the control group receives an inert substance that looks identical to the active treatment, allowing true comparison of treatment effects.

  5. Which study design follows a group of participants over time to assess outcomes?

    Answer: Cohort study

    A cohort study follows a defined group of people (a cohort) over time to observe outcomes, making it effective for studying incidence and causality.

  6. What is the primary purpose of a Phase III clinical trial?

    Answer: Confirming efficacy and monitoring adverse reactions in a large population

    Phase III trials enroll large patient populations to confirm efficacy, monitor adverse reactions, and compare the new treatment to existing standard therapies prior to regulatory approval.